Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock sharply higher in premarket trade, before it surrendered those ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from clinical trials of its weight loss drugs.

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo Nordisk — after just four weeks of treatment. But Viking stock rallied but pulled back from more bullish gains on Monday.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 demonstrate at least 10% weight loss compared with 4% for placebo. The trial is conducted in 28 days. And those with the highest dose of 100 mg lost an average of 8.2% of body weight.

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage biopharma announced Monday. In a study that tested the highest dosage of 100-mg, the drug — known as KV2735 — resulted in an average of 6.8% body weight reduction after 28 days compared to placebo.

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space. Viking reported positive results for its new obesity pill,

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories of the American company Viking Therapeutics, which has achieved a